Asian Spectator

ACN Newswire Business

Eisai to Present Abstracts on Oncology Products and Pipeline at 43rd Annual San Antonio Breast Cancer Symposium

  • Written by ACN Newswire - Press Releases

Eisai to Present Abstracts on Oncology Products and Pipeline at 43rd Annual San Antonio Breast Cancer Symposium

TOKYO, Dec 4, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib"), eribulin mesylate (product name: Halaven, halichondrin class microtubule dynamics inhibitor, "eribulin"), and H3B-6545 (selective estrogen alpha receptor covalent antagonist), discovered at Eisai's U.S. research subsidiary H3 Biomedicine Inc., will be given at the 43rd San Antonio Breast Cancer Symposium (SABCS2020) Virtual Meeting, from December 8 to 11, 2020, in San Antonio, Texas in the United States.At this symposium, regarding the combination therapy with lenvatinib and the anti-PD-1 therapy pembrolizumab (product name: KEYTRUDA) from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside of the United States and Canada), the results of the triple-negative breast cancer cohort in the basket-type Phase II clinical study (LEAP-005) for 6 types of previously treated, advanced solid tumors (Abstract No: PS12-07) is scheduled to be presented.

The results of analysis evaluating eribulin in the clinical practice in a subgroup of patients with metastatic breast cancer with a poor prognosis, in the United States, (Abstract No: PS13-37) will be published.

In addition, regarding H3B-6545, the results of evaluating tolerability, safety, and efficacy of Phase I/II clinical study for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (Abstract No: PD8-06) and others will be presented.In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

CGTN: Hand in Hand: China calls for multilateralism to tackle ...

BEIJING, Jan. 26, 2021 /PRNewswire-Asianet/ -- Against the backdrop of a pandemic that has taken tolls on global public health and put the world economy in deep recession, the world in 2020 ...

Ridesharing App OBHAI On WhatsApp – A First in Bangladesh

DHAKA, Bangladesh, 25 January 2021/PRNewswire-AsiaNet/ -- OBHAI, the home-grown ride-sharing company of Bangladesh is 1st among its peers to recognize the potential benefits of WhatsApp and ...

VIB disclosed Financial Statements FY20: Sustainable growth dr...

HO CHI MINH CITY, Vietnam, Jan. 25, 2021 /PRNewswire-AsiaNet/ -- Vietnam International Bank (VIB) has published Financial Statements FY20, a year with many prosperities in terms of growth ra...

Verofax is the Winner of Bahrain Islamic Bank's 'BisB Innovation Challenge'

BAHRAIN, Jan 25, 2021 - (ACN Newswire) - Bahrain Islamic Bank (BisB), a leading Bank in the Arab Gulf region, has announced Verofax as winner of the 'BisB Innovation Challenge', a Fintech C...

High net worth professionals prefer Ireland's IIP for investment immigration due to the greater flexibility and cost certainty it offers

HONG KONG, Jan 25, 2021 - (ACN Newswire) - Ireland has emerged as a preferred migration destination among Hong Kong's high net worth families and professionals. This is evidenced by the mor...

TIME Interconnect Technology Limited 2020 Corporate Overview

HONG KONG, Jan 25, 2021 - (ACN Newswire) - Despite the negative impact of COVID-19 on the global economic growth in the past year, the Group obtained solid financial performance.The Group h...

Magazine

Australian startup CareApp receives funding injection to expand app

Australian based startup CareApp has recently raised over $500,000 in funding including $250,000 provided by the South Australian State Government to rapidly expand and scale up their smartphone...

Shaparency launches to enable businesses to go fully digital

New venture developed for post-Covid-19 corporate landscape London-based start-up Shaparency, which has been established in response to the business conditions resulting from Covid-19, announces ...

Specops Significant Cyber Attacks

The prevalence and severity of cyber attacks are increasing at an alarming rate every year. So much so, that statistics from Cybersecurity Ventures estimate that cybercrime will cost the global ...

Writers Wanted



News Co Media Group

Content & Technology Connecting Global Audiences

More Information - Less Opinion